Skip to Content

Rule

New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendments.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during November and December 2014. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect a change of sponsorship of eight NADAs and nine ANADAs, and to make correcting amendments for a drug labeler code.

DATES:

This rule is effective March 13, 2015.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, george.haibel@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during November and December 2014, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm.

In addition, Pennfield Oil Co., 14040 Industrial Rd., Omaha, NE 68144, has transferred ownership of, and all rights and interest in, the following approved applications to Pharmgate LLC, 161 North Franklin Turnpike, Suite 2C, Ramsey, NJ 07446:

File No.Product name21 CFR Cite
065-480Chlortetracycline Soluble Powder520.441.
138-934PENNCHLOR SP (chlortetracycline, sulfamethazine, penicillin) Type A medicated articles558.145.
138-935PENNCHLOR (chlortetracycline) Type A medicated articles558.128.
138-938PENNOX (oxytetracycline) Type A medicated articles558.450.
138-939NEO-OXY (neomycin sulfate and oxytetracycline) Type A medicated articles558.455.
140-680TYLAN (tylosin phosphate) Type A medicated articles558.625.
140-681TYLAN Sulfa-G (tylosin phosphate and sulfamethazine) Type A medicated articles558.630.
141-137PENITRACIN (bacitracin methylenedisalicylate) 50 Type A medicated articleNot codified.
200-026PENNOX 343 (oxytetracycline)520.1660d.
200-154PENNOX 200 (oxytetracycline)558.450.
200-295PENNCHLOR 64 (chlortetracycline)558.128.
200-314PENNCHLOR S (chlortetracycline)558.140.
200-354PENNCHLOR (chlortetracycline)/COBAN (monensin)558.355.
200-356PENNCHLOR (chlortetracycline)/DENAGARD (tiamulin)558.600.
Start Printed Page 13227
200-357PENNCHLOR (chlortetracycline)/BIO-COX (salinomycin)558.550.
200-358PENNCHLOR (chlortetracycline)/BMD (bacitracin MD)558.76.
200-359PENNCHLOR (chlortetracycline)/DECCOX (decoquinate)558.195.

At this time, the regulations are being amended to reflect these changes of sponsorship. Following these changes of sponsorship, Pharmgate LLC will now be the sponsor of an approved application while Pennfield Oil Co. will no longer be the sponsor of an approved application. Also, Hikma Pharmaceuticals LLC, P.O. Box 182400, Bayader Wadi Seer, Amman, Jordan 11118, has informed FDA that it has changed its name to Hikma International Pharmaceuticals LLC. Accordingly, § 510.600 (21 CFR 510.600) is being amended to reflect these changes. In addition, FDA is amending § 510.600 and several sections of part 520 to reflect a correct drug labeler code for Akorn Animal Health, Inc. FDA is also amending the regulations in 21 CFR parts 520, 522, 556, and 558 to redesignate several sections to reflect alphabetical order and to make minor technical amendments. These corrections and technical amendments are being made to improve the accuracy of the animal drug regulations.

Table 1—Original and Supplemental NADAs and ANADAs Approved During November and December 2014

NADA/ ANADASponsorNew animal drug product nameAction21 CFR SectionsFOIA SummaryNEPA Review
200-575Putney, Inc., One Monument Sq., suite 400, Portland, ME 04101Carprofen Chewable TabletsOriginal approval as a generic copy of NADA 141-111520.309yesCE 12
141-232Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007SIMPLICEF (cefpodoxime proxetil) Chewable TabletsSupplemental approval of chewable tablet dosage form for dogs520.370yesCE 13
200-512Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007TRIAMULOX (tiamulin hydrogen fumarate) Liquid ConcentrateOriginal approval as a generic copy of NADA 140-916520.2455yesCE 12
200-573Putney, Inc., One Monument Sq., suite 400, Portland, ME 04101Dexmedetomidine HCl (dexmedetomidine hydrochloride) Injectable SolutionOriginal approval as a generic copy of NADA 141-267522.558yesCE 12
141-068Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201BAYTRIL 100 (enrofloxacin) Injectable SolutionSupplemental approval adding administration by intramuscular injection in swine and an indication for control of colibacillosis in groups or pens of weaned pigs522.812yes CE14
141-349Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007DRAXXIN 25 (tulathromycin) Injectable SolutionSupplemental approval for treatment of bovine respiratory disease (BRD) in suckling calves, dairy calves, and veal calves522.2630yesCE 14
141-437Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408OSURNIA (florfenicol, terbinafine, betamethasone acetate) Otic GelOriginal approval for the treatment of otitis externa in dogs524.955yesCE 13
034-267Intervet, Inc., 556 Morris Ave., Summit, NJ 07901GENTOCIN DURAFILM (gentamicin sulfate and betamethasone) Ophthalmic SolutionSupplemental approval of additional safety information524.1044iyesCE 13
141-034Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, BulgariaGAINPRO (bambermycins) Type A medicated articleSupplemental approval of a free-choice Type C medicated loose mineral feed without selenium for pasture cattle558.95yesCE 12
200-510 5Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446DERACIN (chlortetracycline) Type A medicated articlesOriginal approval as a generic copy of NADA 048-761558.128yesCE 12
141-258Intervet, Inc., 556 Morris Ave., Summit, NJ 07901ZILMAX (zilpaterol hydrochloride) Type A medicated articleSupplemental approval to provide for component feeding of Type C medicated feeds558.665yesCE 12
Start Printed Page 13228
141-276 5Intervet, Inc., 556 Morris Ave., Summit, NJ 07901ZILMAX (zilpaterol hydrochloride) plus RUMENSIN (monensin) plus TYLAN (tylosin phosphate) Type C medicated feedsSupplemental approval to provide for component feeding of combination drug Type C medicated feeds558.665yesCE 16
1 The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment.
2 CE granted under 21 CFR 25.33(a)(1).
3 CE granted under 21 CFR 25.33(d)(1).
4 CE granted under 21 CFR 25.33(d)(5).
5 This application is affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,” December 2013.
6 CE granted under 21 CFR 25.33(a)(2).

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

21 CFR Part 510

  • Administrative practice and procedure
  • Animal drugs
  • Labeling
  • Reporting and recordkeeping requirements

21 CFR Parts 520, 522, and 524

  • Animal drugs

21 CFR Part 556

  • Animal drugs
  • Foods

21 CFR Part 558

  • Animal drugs
  • Animal feeds
End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, 556, and 558 are amended as follows:

Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for 21 CFR part 510 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Amend § 510.600 as follows:

End Amendment Part Start Amendment Part

a. In the table in paragraph (c)(1), in the entry for “Akorn Animal Health, Inc.”, in the ”Drug labeler code” column, remove “053599”, and in its place add “059399”;

End Amendment Part Start Amendment Part

b. In the table in paragraph (c)(1), in the entry for “Hikma Pharmaceuticals LLC”, in the “Firm name and address” column, remove “Hikma Pharmaceuticals LLC”, and in its place add “Hikma International Pharmaceuticals LLC”;

End Amendment Part Start Amendment Part

c. In the table in paragraph (c)(1), remove the entry for “Pennfield Oil Co.” and add an entry, in alphabetical order, for “Pharmgate LLC”;

End Amendment Part Start Amendment Part

d. In the table in paragraph (c)(2), remove the entries for “000008”, “048164”, and “053599” and add entries, in numerical order, for “059399” and “069254”; and

End Amendment Part Start Amendment Part

e. In the table in paragraph (c)(2), in the entry for “059115”, in the “Firm name and address” column, remove “Hikma Pharmaceuticals LLC”, and in its place add “Hikma International Pharmaceuticals LLC”.

End Amendment Part

The additions and revisions read as follows:

Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(1) * * *

Firm name and addressDrug labeler code
*         *         *         *         *         *         *
Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446069254
*         *         *         *         *         *         *

(2) * * *

Drug labeler codeFirm name and address
*         *         *         *         *         *         *
059399Akorn Animal Health, Inc., 1925 West Field Ct., suite 300, Lake Forest, IL 60045
*         *         *         *         *         *         *
069254Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446
Start Printed Page 13229
*         *         *         *         *         *         *
Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for 21 CFR part 520 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Redesignated as §§ 520.301 and 520.302]
Start Amendment Part

4. Redesignate §§ 520.310 and 520.312 as §§ 520.301 and 520.302, respectively.

End Amendment Part
[Redesignated as § 520.304 and Amended]
Start Amendment Part

5. Redesignate § 520.309 as § 520.304 and revise newly redesignated § 520.304 by adding paragraph (b)(3) to read as follows:

End Amendment Part
Carprofen.
* * * * *

(b) * * *

(3) No. 026637 for use of product described in paragraph (a)(2) of this section as in paragraph (d) of this section.

* * * * *
Start Amendment Part

6. In § 520.370, revise paragraphs (a) and (b) and in paragraph (c)(2), remove “ intermedius” and in its place add “pseudintermedius” to read as follows:

End Amendment Part
Cefpodoxime tablets.

(a) Specifications. (1) Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime.

(2) Each chewable tablet contains cefpodoxime proxetil equivalent to 100 or 200 mg cefpodoxime.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for uses as follows:

(1) No. 026637 for use of product in paragraph (a)(1) of this section as in paragraph (c) of this section.

(2) No. 054771 for use of products in paragraph (a) of this section as in paragraph (c) of this section.

* * * * *
[Amended]
Start Amendment Part

7. In § 520.441, in paragraph (b)(1), remove “048164” and in its place add “069254”.

End Amendment Part Start Amendment Part

8. Amend § 520.1660d as follows:

End Amendment Part Start Amendment Part

a. In paragraph (b)(6), remove “048164” and in its place add “069254”.

End Amendment Part Start Amendment Part

b. In paragraphs (d)(1)(ii)(A)( 3), (d)(1)(ii)(B)(3), and (d)(1)(ii)(C)(3), revise the last sentence.

End Amendment Part

The revisions read as follows:

Oxytetracycline powder.
* * * * *

(d) * * *

(1) * * *

(ii) * * *

(A) * * *

(3) * * * Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(B) * * *

(3) * * * Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(C) * * *

(3) * * * Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

* * * * *
Start Amendment Part

9. In § 520.2455, revise paragraphs (b)(3) and (c) to read as follows:

End Amendment Part
Tiamulin.
* * * * *

(b) * * *

(3) No. 054771 for the product described in paragraph (a)(3) of this section.

(c) Related tolerances. See § 556.732 of this chapter.

* * * * *
Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

10. The authority citation for 21 CFR part 522 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

11. In § 522.246, in paragraph (b)(3), remove “053599” and in its place add “059399”.

End Amendment Part Start Amendment Part

12. In § 522.558, revise paragraphs (a) and (b) to read as follows:

End Amendment Part
Dexmedetomidine.

(a) Specifications. Each milliliter of solution contains:

(1) 0.1 milligrams (mg) dexmedetomidine hydrochloride; or

(2) 0.5 mg dexmedetomidine hydrochloride.

(b) Sponsors. See sponsors in in § 510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) No. 026637 for use of product described in paragraph (a)(2) of this section;

(2) No. 052483 for use of products described in paragraph (a) of this section.

* * * * *
Start Amendment Part

13. Amend § 522.812 as follows:

End Amendment Part Start Amendment Part

a. Revise paragraph (b)(2);

End Amendment Part Start Amendment Part

b. Remove paragraph (e)(3)(i);

End Amendment Part Start Amendment Part

c. Redesignate paragraphs (e)(3)(ii) and (e)(3)(iii) as paragraphs (e)(3)(i) and (e)(3)(ii), respectively; and

End Amendment Part Start Amendment Part

d. Revise newly redesignated paragraph (e)(3)(i).

End Amendment Part

The revisions read as follows:

Enrofloxacin.
* * * * *

(b) * * *

(2) No. 055529 for use of product described in paragraph (a)(1) of this section as in paragraph (e)(1) of this section, and use of product described in paragraph (a)(2) of this section as in paragraphs (e)(2)(i)(B), (e)(2)(ii)(B), (e)(2)(iii), (e)(3)(i)(B), and (e)(3)(ii) of this section.

* * * * *

(e) * * *

(3) * * *

(i) Amounts and indications for use. (A) Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica, and Mycoplasma hyopneumoniae.

(B) Administer, by subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis.

(C) Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli has been diagnosed.

* * * * *
Start Amendment Part

14. In § 522.1222, revise paragraph (b) to read as follows:

End Amendment Part
Ketamine.
* * * * *
Start Printed Page 13230

(b) Sponsors. See Nos. 000859, 026637, 054628, 054771, 059399, and 063286 in § 510.600(c) of this chapter.

* * * * *
[Amended]
Start Amendment Part

15. In § 522.2474, in paragraph (b), remove “053599” and in its place add “059399”.

End Amendment Part Start Amendment Part

16. In § 522.2630, revise paragraphs (b)(1), (b)(2), (d)(1)(ii)(A), (d)(1)(ii)(B), and (d)(1)(iii) to read as follows:

End Amendment Part
Tulathromycin.
* * * * *

(b) * * *

(1) Product described as in paragraph (a)(1) of this section for use as in paragraphs (d)(1)(i), (d)(1)(ii), (d)(1)(iii)(A), and (d)(2) of this section.

(2) Product described as in paragraph (a)(2) of this section for use as in paragraphs (d)(1)(i), (d)(1)(ii)(B), (d)(1)(iii)(B), and (d)(2) of this section.

* * * * *

(d) * * *

(1) * * *

(ii) * * *

(A) Beef and non-lactating dairy cattle. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. For the control of respiratory disease in cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis. For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.

(B) Suckling calves, dairy calves, and veal calves. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.

(iii) Limitations. (A) Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(B) Calves intended for human consumption must not be slaughtered within 22 days from the last treatment. Not for use in ruminating cattle. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

* * * * *
[Amended]
Start Amendment Part

17. In § 522.2662, in paragraph (b)(4), remove “053599” and in its place add “059399”.

End Amendment Part
[Amended]
Start Amendment Part

18. In § 522.2670, in paragraph (b)(1), remove “053599” and in its place add “059399”.

End Amendment Part Start Part

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

19. The authority citation for 21 CFR part 524 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

20. Add § 524.955 to read as follows:

End Amendment Part
Florfenicol, terbinafine, and betamethasone acetate otic gel.

(a) Specifications. Each milliliter of gel contains 10 milligrams (mg) florfenicol, 10 mg terbinafine, and 1 mg betamethasone acetate.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days.

(2) Indications for use. For the treatment of otitis externa in dogs associated with susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Start Amendment Part

21. In § 524.1044i, revise paragraph (c)(2) to read as follows:

End Amendment Part
Gentamicin and betamethasone ophthalmic solution.
* * * * *

(c) * * *

(2) Indications for use. For treatment of external eye infections and inflammation.

* * * * *
Start Part

PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

End Part Start Amendment Part

22. The authority citation for 21 CFR part 556 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 342, 360b, 371.

End Authority
[Redesignated as § 556.732]
Start Amendment Part

23. Redesignate § 556.738 as § 556.732.

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

24. The authority citation for 21 CFR part 558 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

25. In § 558.76, in paragraph (d)(1)(iv), in the “Limitations” and “Sponsor” columns, remove “048164” and in its place add “069254”.

End Amendment Part Start Amendment Part

26. In § 558.95, add paragraph (d)(4)(v) to read as follows:

End Amendment Part
Bambermycins.
* * * * *

(d) * * *

(4) * * *

(v) Used as a free-choice Type C medicated loose mineral feed for pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers) as follows:

(A) Specifications.

IngredientInternational feed No.Percent
Deflorinated phosphate (20.5% calcium, 18.5% phosphorus)6-01-08042.50
Sodium chloride (salt)6-04-15220.10
Calcium carbonate (38% calcium)6-01-06915.45
Corn distillers dried grains w/solubles5-28-2369.57
Magnesium oxide6-02-7565.15
Vitamin and trace mineral premix *3.72
Mineral oil1.00
Yeast (primary dehydrated yeast)7-05-5330.75
Bambermycins Type A article (10 g/lb)0.60
Iron oxide6-02-4310.50
Magnesium sulfate (67%)6-02-7580.32
Copper sulfate6-01-7200.18
Start Printed Page 13231
Potassium sulfate (0.33%)6-06-0980.16
* Content of vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).

(B) Amount per ton. 120 grams.

(C) Indications for use. For increased rate of weight gain.

(D) Limitations. For free-choice feeding to pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers). Feed a non-medicated commercial mineral product for 6 weeks to stabilize consumption between 2.66 and 10.66 ounces per head per day. Feed continuously to provide 10 to 40 milligrams bambermycins per head per day. Daily bambermycins intakes in excess of 20 mg/head/day have not been shown to be more effective than 20 mg/head/day.

* * * * *
Start Amendment Part

27. Amend § 558.128 as follows:

End Amendment Part Start Amendment Part

a. In paragraph (b)(1), remove “Nos. 054771, 048164, and 066104” and in its place add “Nos. 054771, 066104, and 069254”;

End Amendment Part Start Amendment Part

b. In paragraphs (e)(4)(ii) and (iv), in the “Limitations” column, remove “048164” wherever it occurs and in its place add “069254”;

End Amendment Part Start Amendment Part

c. In paragraphs (e)(1)(i), (ii), and (iii), (e)(2)(i), (ii), (iii), and (iv), (e)(3)(i), (ii), (iii), and (iv), (e)(4)(i), (ii), (iv), (vii), and (viii), and (e)(5)(i) and (ii), in the “Sponsor” column, remove “048164” wherever it occurs and in its place in numerical order add “069254”; and

End Amendment Part Start Amendment Part

d. Revise paragraphs (e)(1)(iv), (e)(4)(v), and (e)(4)(ix).

End Amendment Part

The revisions read as follows:

Chlortetracycline.
* * * * *

(e) * * *

(1) * * *

Chlortetracycline amountIndications for useLimitationsSponsor
*         *         *         *         *         *         *
(iv) 500 g/tonChickens: For the reduction of mortality due to E. coli infections susceptible to chlortetracycline1. Feed for 5 d. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: zero withdrawal time054771, 069254.
2. Feed for 5 d; withdraw 24 h prior to slaughter; do not feed to chickens producing eggs for human consumption012286, 054771, 066104, 069254.
* * * * *

(4) * * *

Chlortetracycline amountIndications for useLimitationsSponsor
*         *         *         *         *         *         *
(v) 500 to 4,000 g/tonCalves, beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by E. coli and bacterial pneumonia caused by P. multocida susceptible to chlortetracyclineFeed continuously for not more than 5 days to provide 10 mg/lb body weight per day. To sponsor No. 054771 under NADA 046-699: 24-h withdrawal time To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: Zero withdrawal time054771 069254
*         *         *         *         *         *         *
(ix) 350 mg/head/day1. Beef cattle: For control of bacterial pneumonia associated with shipping fever complex caused by Pasteurella spp. susceptible to chlortetracyclineWithdraw 48 h prior to slaughter. To sponsor No. 054771 under NADA 046-699: 48-h withdrawal time. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: Zero withdrawal time012286, 054771, 066104, 069254.
2. Beef cattle (under 700 lb): For control of active infection of anaplasmosis caused by A. marginale susceptible to chlortetracyclineWithdraw 48 h prior to slaughter. To sponsor No. 054771 under NADA 046-699: 48-h withdrawal time. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: zero withdrawal time012286, 054771, 066104, 069254.
* * * * *
[Amended]
Start Amendment Part

28. In § 558.140, in paragraph (b)(1), remove “048164” and in its place add “069254”.

End Amendment Part
[Amended]
Start Amendment Part

29. In § 558.145, in paragraph (a)(2), remove “048164” and in its place add “069254”.

End Amendment Part
[Amended]
Start Amendment Part

30. In § 558.195, in paragraph (e)(2)(iv), in the “Limitations” and “Sponsor” columns, remove “048164” and in its place add “069254”.

End Amendment Part
[Amended]
Start Amendment Part

31. In § 558.355, in paragraph (f)(1)(xiv)( b), remove “048164” and in its place add “069254”.

End Amendment Part
Start Printed Page 13232
[Amended]
Start Amendment Part

32. Amend § 558.450 as follows:

End Amendment Part Start Amendment Part

a. In paragraph (a)(2), remove “048164” and in its place add “069254”;

End Amendment Part Start Amendment Part

b. In paragraphs (d)(2)(iii), (d)(2)(iv), and (d)(4)(ii), in the “Limitations” column, remove “048164” wherever it occurs and in its place add “069254”; and

End Amendment Part Start Amendment Part

c. In paragraphs (d)(1)(i), (ii), (iii), and (iv), (d)(2)(i), (ii), (iii), and (iv), (d)(3)(i) and (ii), (d)(4)(i), (ii), (iii), (iv), and (v), and (d)(5)(i), (ii), and (iii), in the “Sponsor” column, remove “048164” and in its place add “069254”.

End Amendment Part
[Amended]
Start Amendment Part

33. Amend § 558.455 as follows:

End Amendment Part Start Amendment Part

a. In paragraph (b), remove “Nos. 048164 and 066104” and in its place add “Nos. 066104 and 069254”; and

End Amendment Part Start Amendment Part

b. In paragraphs (e)(1)(i), (ii), (iii), and (iv), (e)(2)(i), (ii), (iii), and (iv), (e)(3)(i) and (ii), and (e)(4)(i), (ii), (iii), (iv), (v), and (vi), in the “Sponsor” column, remove “048164” and in its place in numerical order add “069254”.

End Amendment Part
[Amended]
Start Amendment Part

34. In § 558.550, in paragraphs (b)(3) and (d)(1)(xvi)( c), remove “048164” and in its place add “069254”.

End Amendment Part
[Redesignated as § 558.612 and Amended]
Start Amendment Part

35. Redesignate § 558.600 as § 558.612 and amend newly redesignated § 558.612 as follows:

End Amendment Part Start Amendment Part

a. In paragraph (c), remove “§ 556.738” and in its place add “§ 556.732”; and

End Amendment Part Start Amendment Part

b. In paragraph (e)(1)(iii), in the “Limitations” and “Sponsor” columns, remove “048164” and in its place in numerical order add “069254”.

End Amendment Part
[Redesignated as § 558.600]
Start Amendment Part

36. Redesignate § 558.615 as § 558.600.

End Amendment Part
[Amended]
Start Amendment Part

37. In § 558.625, in paragraph (b)(5), remove “048164” and in its place add “069254”.

End Amendment Part
[Amended]
Start Amendment Part

38. In § 558.630, in paragraph (b)(2), remove “No. 054771” and in its place add “Nos. 054771 and 069254”.

End Amendment Part Start Amendment Part

39. Amend § 558.665 as follows:

End Amendment Part Start Amendment Part

a. Revise paragraphs (d)(1) and (e)(1);

End Amendment Part Start Amendment Part

b. Redesignate paragraph (d)(2) as paragraph (d)(4); and

End Amendment Part Start Amendment Part

c. Add paragraphs (d)(2), (d)(3), (e)(7), and (e)(8).

End Amendment Part

The revisions and additions read as follows:

Zilpaterol.
* * * * *

(d) * * *

(1) Labeling shall bear the following caution statements: “Zilpaterol hydrochloride is not for use in animals intended for breeding. Do not allow horses or other equines access to feed containing zilpaterol. Do not use in veal calves.”

(2) Labeling of Type A medicated articles and Type B medicated feeds used to manufacture complete Type C medicated feeds shall bear the caution statements in paragraph (d)(3) of this section.

(3) Labeling of complete Type C medicated feeds shall bear the following caution statements: “Not to be fed to cattle in excess of 90 mg zilpaterol/head/day in complete feed. If pen consumption of complete feed exceeds 26.5 lb/head/day (90 percent dry matter basis), zilpaterol should not be fed in complete feed.”

* * * * *

(e) * * *

Zilpaterol in grams/tonCombination grams/tonIndications for useLimitationsSponsor
(1) 6.8Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feedFeed continuously as the sole ration during the last 20 to 40 days on feed to provide 60 to 90 mg/head/day. Withdrawal period: 3 days000061
*         *         *         *         *         *         *
(7) 6.8 to 24Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feedFeed continuously to cattle during the last 20 to 40 days on feed to provide 60 mg zilpaterol hydrochloride per head per day. Withdrawal period: 3 days000061
(8) 6.8 to 24Monensin 10 to 40, plus tylosin 8 to 10Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed; for prevention and control of coccidiosis due to Eimeria bovis and E. zuernii; and for reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Arcanobacterium (Actinomyces) pyogenesFeed continuously to cattle during the last 20 to 40 days on feed to provide 60 mg zilpaterol hydrochloride per head per day. See paragraphs §§ 558.355(d) and 558.625(c). Monensin and tylosin as provided by No. 000986 in § 510.600(c) of this chapter. Withdrawal period: 3 days000061
Start Signature

Dated: March 9, 2015.

Bernadette Dunham,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 2015-05644 Filed 3-12-15; 8:45 am]

BILLING CODE 4164-01-P